SANTA CLARA, Calif., August 20, 2025--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion ...
SANTA CLARA, Calif. - Agilent Technologies Inc. (NYSE:A), a healthcare diagnostics company with strong financial health according to InvestingPro analysis, announced Wednesday that its MMR IHC Panel ...
A novel xenonucleic acid mediated molecular clamping technology for early colorectal cancer diagnostics. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does not ...
Background and Aim: The aim of the present study was to evaluate associations between mismatch repair (MMR) status and clinicopathological characteristics and prognosis using immunohistochemistry (IHC ...
Testing colorectal tumours using either microsatellite instability (MSI) or immunohistochemistry (IHC) testing for mismatch repair (MMR) proteins can identify people in whom the cancer may have ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results